A study focused on how the body handles the compound
MK-1942 is a negative allosteric modulator of the metabotropic glutamate receptor mGluR2. This action represents a pharmacological avenue to explore, not evidence of benefits for memory or depressive symptoms.
Nonclinical experiments suggested that the enzyme CYP2C19 contributes to its metabolism. The researchers therefore studied exposure to MK-1942 after single and repeated doses, accounting for different activity profiles of this enzyme.
The abstract reviewed does not specify the sample size, doses or exact trial duration. It therefore does not allow a detailed assessment of the precision of the results or how representative the participants were.
A difference after a single dose, but not at steady state
After a single dose, total exposure to MK-1942, measured by the area under the concentration–time curve, was approximately 70% higher in CYP2C19 poor metabolizers than in extensive metabolizers. This figure describes exposure to the compound, not an increase in its efficacy.
The researchers then separated the repeated-dose groups according to their CYP2C19 profile. Contrary to expectations based on the single dose, steady-state exposures were similar across profiles. The abstract provides no established explanation for this difference.
Findings that help plan subsequent trials
Total exposure was also comparable under fasting conditions and after a low-fat meal. This observation does not extend to all meals: the abstract reports that an earlier trial had observed reduced exposure after a high-fat meal.
According to the authors, these findings supported allowing a low-fat meal around dosing and not adjusting the dose according to CYP2C19 profile in the subsequent global phase 2 trial. These are research decisions, not recommendations for use.
Administration was described as generally well tolerated. Without details of adverse events in the abstract, this does not establish long-term safety or tolerability in people with Alzheimer’s disease or depression.
Limitations to keep in mind
Only the Europe PMC abstract was reviewed, not the full text. The sample size, doses, duration, detailed comparators and adverse events are not specified in the excerpt. Funding and conflicts of interest have not been verified. Findings in healthy Japanese volunteers demonstrate neither clinical efficacy nor long-term safety in patients.
What we can take away
This study helps prepare subsequent trials of MK-1942. It does not establish whether the compound improves cognition or depressive symptoms.
Sources and provenance
- A Phase 1 Study of MK-1942, a Negative Allosteric Modulator of mGluR2, in Healthy Japanese to Flexibly Assess Factors Including CYP2C19 Phenotype.
Source date: 2026-11-01.
research-article, Clinical Trial, Phase I, Randomized Controlled Trial, Journal Article · Résumé Europe PMC uniquement, texte intégral non consulté